<DOC>
	<DOCNO>NCT00902577</DOCNO>
	<brief_summary>This phase II trial study well positron emission tomography ( PET ) scan use 18F-fluoromisonidazole work give together magnetic resonance imaging ( MRI ) ) assess tumor hypoxia patient newly diagnose glioblastoma multiforme ( GBM ) . Diagnostic procedure , MRI PET scan use 18F-fluoromisonidazole ( FMISO ) , may help predict response tumor treatment allow doctor plan good treatment .</brief_summary>
	<brief_title>MRI PET Scan Using 18F-Fluoromisonidazole In Assessing Tumor Hypoxia Patients With Newly Diagnosed Glioblastoma Multiforme</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine association baseline FMISO PET uptake ( hypoxic volume [ HV ] ) , high tumor : blood ratio [ T/Bmax ] ) MRI parameter ( Ktrans , CBV ) overall survival ( OS ) participants newly diagnose GBM . SECONDARY OBJECTIVES : I . To determine association baseline FMISO PET uptake ( HV , T/Bmax ) MRI parameter ( Ktrans , CBV ) time progression ( TTP ) 6-month progression free survival ( PFS-6 ) participants newly diagnose GBM . II . To assess reproducibility baseline FMISO PET uptake parameter implement baseline `` test '' `` retest '' PET scan ( perform within 1 7 day ) . III . To assess correlation high tissue : cerebellum ratio [ T/Cmax ] T/Bmax baseline . IV . To assess correlation MRI parameter ( T1Gd , VCI , CBV-S , ADC , NAA-Cho , BOLD , T2 ) OS , TTP , PFS-6 . OUTLINE : This multicenter study . Two week initiation chemoradiotherapy temozolomide , patient undergo MRI PET scan use FMISO . A subset 15 patient undergo FMISO PET scan approximately 1 week chemoradiotherapy . Blood sample collect baseline periodically study compare image measure tissue uptake FMISO blood concentration . Tumor sample collect diagnostic biopsy surgery analysis tumor hypoxic marker methylguanine methyl transferase immunohistochemical PCR assay . After completion study therapy , patient follow every 3 month 5 year .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Gliosarcoma</mesh_term>
	<mesh_term>Misonidazole</mesh_term>
	<criteria>Must able provide write informed consent Newly diagnose GBM , World Health Organization ( WHO ) grade IV base pathology confirmation Residual tumor surgery ( amount residual tumor impact patient eligibility visible residual disease include T2/FLAIR hyperintensity ) NOTE : If patient biopsy , postoperative MRI need assess residual tumor prior enrollment Scheduled receive standard fractionate radiation therapy Scheduled receive TMZ addition radiation therapy Karnofsky Performance Score &gt; 60 Pregnant breastfeeding ( female childbearing potential , unsure pregnancy status , standard urine pregnancy test do ) Scheduled receive chemotherapy , immunotherapy , investigational agent trial unwilling share data ACRIN ( i.e. , additional therapy add radiation TMZ allow ACRIN able obtain treatment information ) Not suitable undergo MRI use contrast agent Gd : Claustrophobia Presence metallic object implant medical device body ( i.e. , cardiac pacemaker , aneurysm clip , surgical clip , prosthesis , artificial heart , valve steel part , metal fragment , shrapnel , tattoo near eye , steel implant ) Sickle cell disease Renal failure Reduced renal function , determine GFR &lt; 30 mL/min/1.73 m^2 base serum creatinine level obtain within 28 day prior registration Presence coexist condition , judgment investigator , might increase risk subject Presence serious systemic illness , include : uncontrolled intercurrent infection , uncontrolled malignancy , significant renal disease , psychiatric/social situation might impact survival endpoint study limit compliance study requirement History allergic reaction attribute compound similar chemical biologic composition FMISO ; allergic reaction nitroimidazoles highly unlikely Not suitable undergo PET MRI , include weight great 350 lb ( weight limit MRI PET table ) Prior treatment implant radiotherapy chemotherapy source wafer polifeprosan 20 carmustine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>